Literature DB >> 29891200

Magnetic Resonance, Vendor-independent, Intensity Histogram Analysis Predicting Pathologic Complete Response After Radiochemotherapy of Rectal Cancer.

Nicola Dinapoli1, Brunella Barbaro2, Roberto Gatta1, Giuditta Chiloiro2, Calogero Casà2, Carlotta Masciocchi3, Andrea Damiani1, Luca Boldrini2, Maria Antonietta Gambacorta2, Michele Dezio2, Gian Carlo Mattiucci2, Mario Balducci2, Johan van Soest4, Andre Dekker4, Philippe Lambin4, Claudio Fiorino5, Carla Sini5, Francesco De Cobelli6, Nadia Di Muzio7, Calogero Gumina7, Paolo Passoni7, Riccardo Manfredi2, Vincenzo Valentini2.   

Abstract

PURPOSE: The objective of this study is finding an intensity based histogram (IBH) signature to predict pathologic complete response (pCR) probability using only pre-treatment magnetic resonance (MR) and validate it externally in order to create a workflow for the external validation of an MR IBH signature and to apply the model out of the environment where it has been tuned. The impact of pCR and the final predictors on the survival outcome were also evaluated. METHODS AND MATERIALS: Three centers using different MR scanners were involved in this retrospective study. The first center recruited 162 patients for model training, and the second and third centers provided 34 plus 25 patients for external validation. Patients provided written consent. Accrual period was from May 2008 to December 2014. After surgery pathologic response was defined. T2-weighted MR scans acquired before chemoradiation therapy (CRT) were used for analysis addressed on primary lesions. Images were pre-processed using Laplacian of Gaussian (LoG) filter with multiple σ, and first order intensity histogram-based features (kurtosis, skewness, and entropy) were extracted. Features selection was performed using Mann-Whitney test. Tumor staging (cT, cN) was added to build a logistic regression model and predict pCR. Model performance was evaluated with internal and external validation using area under the curve (AUC) of the receiver operator characteristic (ROC) and calibration with Hosmer-Lemeshow test. The linear cross-correlation matrix (Pearson's coefficient) and the variance inflation factor (VIF) were used to check the correlation and the co-linearity among the final predictors. The amount of the information added through the radiomics features was estimated by using the DeLong's test, and the impact of pCR and the final predictors on survival outcomes were evaluated through the Kaplan-Meier curves by using the log-rank test and the multivariate Cox model.
RESULTS: Candidate-to-analysis features were skewness (σ = 0.485, P value = .01) and entropy (σ = 0.344, P value < .05). Logistic regression analysis showed as significant covariates cT (P value < .01), skewness-σ = 0.485 (P value = .01), and entropy-σ = 0.344 (P value < .05). Model AUCs were 0.73 (internal) and 0.75 (external).
CONCLUSIONS: This MR-based, vendor-independent model can be helpful for predicting pCR probability in locally advanced rectal cancer (LARC) patients only using pre-treatment imaging.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29891200     DOI: 10.1016/j.ijrobp.2018.04.065

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  36 in total

1.  Predicting locally advanced rectal cancer response to neoadjuvant therapy with 18F-FDG PET and MRI radiomics features.

Authors:  V Giannini; S Mazzetti; I Bertotto; C Chiarenza; S Cauda; E Delmastro; C Bracco; A Di Dia; F Leone; E Medico; A Pisacane; D Ribero; M Stasi; D Regge
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-13       Impact factor: 9.236

2.  Predicting the tumor response to chemoradiotherapy for rectal cancer: Model development and external validation using MRI radiomics.

Authors:  Philippe Bulens; Alice Couwenberg; Martijn Intven; Annelies Debucquoy; Vincent Vandecaveye; Eric Van Cutsem; André D'Hoore; Albert Wolthuis; Pritam Mukherjee; Olivier Gevaert; Karin Haustermans
Journal:  Radiother Oncol       Date:  2019-08-17       Impact factor: 6.280

3.  Analysis of MRI and CT-based radiomics features for personalized treatment in locally advanced rectal cancer and external validation of published radiomics models.

Authors:  Iram Shahzadi; Alex Zwanenburg; Annika Lattermann; Annett Linge; Christian Baldus; Jan C Peeken; Stephanie E Combs; Markus Diefenhardt; Claus Rödel; Simon Kirste; Anca-Ligia Grosu; Michael Baumann; Mechthild Krause; Esther G C Troost; Steffen Löck
Journal:  Sci Rep       Date:  2022-06-17       Impact factor: 4.996

4.  Combined artificial intelligence and radiologist model for predicting rectal cancer treatment response from magnetic resonance imaging: an external validation study.

Authors:  Natally Horvat; Harini Veeraraghavan; Caio S R Nahas; David D B Bates; Felipe R Ferreira; Junting Zheng; Marinela Capanu; James L Fuqua; Maria Clara Fernandes; Ramon E Sosa; Vetri Sudar Jayaprakasam; Giovanni G Cerri; Sergio C Nahas; Iva Petkovska
Journal:  Abdom Radiol (NY)       Date:  2022-06-16

5.  Whole lesion histogram analysis of apparent diffusion coefficient predicts therapy response in locally advanced rectal cancer.

Authors:  Mayra Evelia Jiménez de Los Santos; Juan Armando Reyes-Pérez; Victor Domínguez Osorio; Yolanda Villaseñor-Navarro; Liliana Moreno-Astudillo; Itzel Vela-Sarmiento; Isabel Sollozo-Dupont
Journal:  World J Gastroenterol       Date:  2022-06-21       Impact factor: 5.374

6.  Combining Radiomics and Blood Test Biomarkers to Predict the Response of Locally Advanced Rectal Cancer to Chemoradiation.

Authors:  Seung Hyuck Jeon; Changhoon Song; Eui Kyu Chie; Bohyoung Kim; Young Hoon Kim; Won Chang; Yoon Jin Lee; Joo-Hyun Chung; Jin Beom Chung; Keun-Wook Lee; Sung-Bum Kang; Jae-Sung Kim
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

7.  Radiomic Features of Primary Rectal Cancers on Baseline T2 -Weighted MRI Are Associated With Pathologic Complete Response to Neoadjuvant Chemoradiation: A Multisite Study.

Authors:  Jacob T Antunes; Asya Ofshteyn; Kaustav Bera; Erik Y Wang; Justin T Brady; Joseph E Willis; Kenneth A Friedman; Eric L Marderstein; Matthew F Kalady; Sharon L Stein; Andrei S Purysko; Rajmohan Paspulati; Jayakrishna Gollamudi; Anant Madabhushi; Satish E Viswanath
Journal:  J Magn Reson Imaging       Date:  2020-03-26       Impact factor: 4.813

8.  Delta-radiomics increases multicentre reproducibility: a phantom study.

Authors:  Valerio Nardone; Alfonso Reginelli; Cesare Guida; Maria Paola Belfiore; Michelangelo Biondi; Maria Mormile; Fabrizio Banci Buonamici; Eugenio Di Giorgio; Marco Spadafora; Paolo Tini; Roberta Grassi; Luigi Pirtoli; Pierpaolo Correale; Salvatore Cappabianca; Roberto Grassi
Journal:  Med Oncol       Date:  2020-03-31       Impact factor: 3.064

9.  Histogram peritumoral enhanced features on MRI arterial phase with extracellular contrast agent can improve prediction of microvascular invasion of hepatocellular carcinoma.

Authors:  Xinxin Wang; Yunfeng Sun; Xueyan Zhou; Zhiwei Shen; Hongxia Zhang; Jiqing Xing; Yang Zhou
Journal:  Quant Imaging Med Surg       Date:  2022-02

10.  Does restaging MRI radiomics analysis improve pathological complete response prediction in rectal cancer patients? A prognostic model development.

Authors:  Giuditta Chiloiro; Davide Cusumano; Paola de Franco; Jacopo Lenkowicz; Luca Boldrini; Davide Carano; Brunella Barbaro; Barbara Corvari; Nicola Dinapoli; Martina Giraffa; Elisa Meldolesi; Riccardo Manfredi; Vincenzo Valentini; Maria Antonietta Gambacorta
Journal:  Radiol Med       Date:  2021-11-01       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.